{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:30:49Z","timestamp":1783042249082,"version":"3.54.6"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ctrv.2025.103039","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:03:55Z","timestamp":1760731435000},"page":"103039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Mismatch repair deficiency\/microsatellite instability (dMMR\/MSI-H) in rectal cancer patients treated with standard neoadjuvant therapy: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"141","author":[{"given":"Gianluca","family":"Ricco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Gallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Benhima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc Van","family":"Laethem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sclafani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ctrv.2025.103039_b0005","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"issue":"7683","key":"10.1016\/j.ctrv.2025.103039_b0010","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature24673","article-title":"Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth","volume":"552","author":"Germano","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103039_b0015","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/S0002-9440(10)65436-3","article-title":"High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability","volume":"154","author":"Dolcetti","year":"1999","journal-title":"Am J Pathol"},{"issue":"20","key":"10.1016\/j.ctrv.2025.103039_b0020","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1158\/1078-0432.CCR-09-1438","article-title":"Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, MSI and CpG Island Methylator Phenotype","volume":"15","author":"Ogino","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103039_b0025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2007.04.044","article-title":"Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study","volume":"133","author":"Jenkins","year":"2007","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103039_b0030","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.1016\/j.cgh.2021.04.021","article-title":"Universal immunohistochemistry for lynch syndrome: a systematic review and meta-analysis of 58,580 colorectal carcinomas","volume":"20","author":"Eikenboom","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"20","key":"10.1016\/j.ctrv.2025.103039_b0035","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","article-title":"Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer","volume":"28","author":"Sargent","year":"2010","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103039_b0040","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1245\/s10434-015-4807-6","article-title":"Defective mismatch repair status was not associated with DFS and OS in stage II colon cancer treated with adjuvant chemotherapy","volume":"22","author":"Kim","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103039_b0045","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/jnci\/djr153","article-title":"DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy","volume":"103","author":"Sinicrope","year":"2011","journal-title":"J National Cancer Institute"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103039_b0050","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1200\/JCO.20.01600","article-title":"Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials","volume":"39","author":"Cohen","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103039_b0055","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejca.2020.11.016","article-title":"Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials","volume":"144","author":"Sinicrope","year":"2021","journal-title":"European J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103039_b0060","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.2005.01.086","article-title":"Systematic review of microsatellite instability and colorectal cancer prognosis","volume":"23","author":"Popat","year":"2005","journal-title":"J Clinical Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103039_b0065","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1056\/NEJMoa022289","article-title":"Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer","volume":"349","author":"Ribic","year":"2003","journal-title":"New England J Medicine"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103039_b0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0016-5085(99)70558-5","article-title":"Mismatch repair proficiency and in vitro response to 5-fluorouracil","volume":"117","author":"Carethers","year":"1999","journal-title":"Gastroenterology"},{"issue":"21","key":"10.1016\/j.ctrv.2025.103039_b0075","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability\u2013high metastatic colorectal cancer","volume":"391","author":"Andr\u00e9","year":"2024","journal-title":"New England J Medicine"},{"issue":"10476","key":"10.1016\/j.ctrv.2025.103039_b0080","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103039_b0085","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103039_b0090","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ctrv.2025.103039_b0095","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ctrv.2025.103039_b0100","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"neoadjuvant immunotherapy in locally advanced mismatch repair\u2013deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"New England J Medicine"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103039_b0105","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1038\/s41591-024-03250-w","article-title":"Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial","volume":"30","author":"de Gooyer","year":"2024","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.ctrv.2025.103039_b0110","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMc2210175","article-title":"Prevalence of mismatch-repair deficiency in rectal adenocarcinomas","volume":"387","author":"Papke","year":"2022","journal-title":"New England J Medicine"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103039_b0115","first-page":"188","article-title":"Incidence and outcomes of patients with mismatch repair deficient rectal cancer operated in 2016: a nationwide cohort from the Netherlands","volume":"24","author":"van Geffen","year":"2025","journal-title":"Clin Colorectal Cancer"},{"issue":"4_suppl","key":"10.1016\/j.ctrv.2025.103039_b0120","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1200\/JCO.2018.36.4_suppl.806","article-title":"Microsatellite instability as a predictive marker for response to neoadjuvant chemoradiation in locally advanced rectal cancer","volume":"36","author":"Shulman","year":"2018","journal-title":"JCO"},{"issue":"13","key":"10.1016\/j.ctrv.2025.103039_b0125","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/1078-0432.CCR-19-3728","article-title":"Mismatch repair\u2013deficient rectal cancer and resistance to neoadjuvant chemotherapy","volume":"26","author":"Cercek","year":"2020","journal-title":"Clinical Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103039_b0130","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/his.14710","article-title":"Microsatellite instability in rectal cancer: what does it mean? A study of two randomized trials and a systematic review of the literature","volume":"81","author":"Swets","year":"2022","journal-title":"Histopathology"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103039_b0135","doi-asserted-by":"crossref","first-page":"491","DOI":"10.21037\/atm-22-124","article-title":"The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy","volume":"10","author":"Wu","year":"2022","journal-title":"Ann Transl Med"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103039_b0140","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"23","key":"10.1016\/j.ctrv.2025.103039_b0145","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative management of mismatch repair\u2013deficient tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"New England J Medicine"},{"issue":"25","key":"10.1016\/j.ctrv.2025.103039_b0150","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"New England J Medicine"},{"key":"10.1016\/j.ctrv.2025.103039_b0155","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1016\/j.annonc.2024.08.573","article-title":"504O IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR\/MSI tumors: results of the colorectal cancer cohort","volume":"35","author":"de la Fouchardiere","year":"2024","journal-title":"Annals of Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103039_b0160","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103039_b0165","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S2468-1253(22)00439-3","article-title":"Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study","volume":"8","author":"Chen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103039_b0170","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High\/Deficient Mismatch Repair Solid Tumors","volume":"41","author":"Ludford","year":"2023","journal-title":"JCO"},{"issue":"S13","key":"10.1016\/j.ctrv.2025.103039_b0175","doi-asserted-by":"crossref","first-page":"S1564","DOI":"10.21037\/jtd.2018.01.131","article-title":"Do immune checkpoint inhibitors need new studies methodology?","volume":"10","author":"Ferrara","year":"2018","journal-title":"J Thorac Dis"},{"issue":"372","key":"10.1016\/j.ctrv.2025.103039_b0180","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"29","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103039_b0185","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Systematic Rev"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103039_b0190","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2559.2005.02176.x","article-title":"Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer","volume":"47","author":"Ryan","year":"2005","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2025.103039_b0195","doi-asserted-by":"crossref","unstructured":"Amin, Mahul B et al. \u201cThe Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u2018personalized\u2019 approach to cancer staging.\u201d CA: a cancer journal for clinicians vol. 67(2) (2017) 93-99. doi:10.3322\/caac.21388.","DOI":"10.3322\/caac.21388"},{"key":"10.1016\/j.ctrv.2025.103039_b0200","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/DCR.0000000000000266","article-title":"American Joint Committee on Cancer and College of American Pathologists regression grade: a new prognostic factor in rectal cancer","volume":"58","author":"Mace","year":"2015","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103039_b0205","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s003840050072","article-title":"Pathological features of rectal cancer after preoperative radiochemotherapy","volume":"12","author":"Dworak","year":"1997","journal-title":"Int J Colorectal Disease"},{"key":"10.1016\/j.ctrv.2025.103039_b0210","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available from: URL: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm."},{"key":"10.1016\/j.ctrv.2025.103039_b0215","unstructured":"REACCT Collaborative. Microsatellite instability in young patients with rectal cancer: molecular findings and treatment response. British Journal of Surgery. 109(3) 2022 251\u20135."},{"issue":"3","key":"10.1016\/j.ctrv.2025.103039_b0220","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4174\/astr.2022.103.3.176","article-title":"Association between microsatellite instability and tumor response to neoadjuvant chemoradiotherapy for rectal cancer","volume":"103","author":"Lee","year":"2022","journal-title":"Ann Surg Treat Res"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103039_b0225","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5306\/wjco.v9.i7.133","article-title":"Mismatch repair protein expression and intratumoral budding in rectal cancer are associated with an increased pathological complete response to preoperative chemoradiotherapy: a case-control study","volume":"9","author":"Lino-Silva","year":"2018","journal-title":"World J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103039_b0230","first-page":"188","article-title":"Incidence and outcomes of patients with mismatch repair deficient rectal cancer operated in 2016: a nationwide cohort from the Netherlands","volume":"24","author":"van Geffen","year":"2025","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103039_b0235","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00384-024-04604-z","article-title":"Association between microsatellite status and characteristics and outcomes of early-onset compared to late-onset rectal cancer","volume":"39","author":"Emile","year":"2024","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.ctrv.2025.103039_b0240","doi-asserted-by":"crossref","DOI":"10.1177\/15330338231202893","article-title":"A predictive model to evaluate pathologic complete response in rectal adenocarcinoma","author":"Qing","year":"2023","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2025.103039_b0245","doi-asserted-by":"crossref","DOI":"10.1177\/10732748231214936","article-title":"Cytokeratin 7 expression and mismatch repair status for survival prediction in patients with low rectal cancer after neoadjuvant therapy","author":"Shi","year":"2023","journal-title":"Cancer Control"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103039_b0250","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41416-023-02444-2","article-title":"Mismatch Repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy","volume":"129","author":"Pretta","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2025.103039_b0255","unstructured":"Ni K, Zhan Y, Liu Z. Mismatch repair system deficiency is associated with chemoradiotherapy resistance in locally advanced rectal adenocarcinoma patients."},{"key":"10.1016\/j.ctrv.2025.103039_b0260","article-title":"Survival outcomes analysis according to mismatch repair status in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103039_b0265","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1097\/PAS.0000000000001918","article-title":"DNA mismatch repair\u2013deficient rectal cancer is frequently associated with lynch syndrome and with poor response to neoadjuvant therapy","volume":"46","author":"Farchoukh","year":"2022","journal-title":"American J Surgical Pathology"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103039_b0270","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13304-019-00697-2","article-title":"Do microsatellite instability (MSI) and deficient mismatch repair (dMMR) affect the pathologic complete response (pCR) in patients with rectal cancer who received neoadjuvant treatment?","volume":"72","author":"Acar","year":"2020","journal-title":"Updates Surg"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103039_b0275","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.21873\/invivo.12017","article-title":"Microsatellite instability correlated inflammatory markers and their prognostic value in the rectal cancer following neoadjuvant chemoradiotherapy: a hypothesis-generating study","volume":"34","author":"Lee","year":"2020","journal-title":"In Vivo"},{"key":"10.1016\/j.ctrv.2025.103039_b0280","doi-asserted-by":"crossref","unstructured":"Ye SB, Cheng YK, Zhang L, Zou YF, Chen P, Deng YH, et al. Association of mismatch repair status with survival and response to neoadjuvant chemo(radio)therapy in rectal cancer. npj Precis Onc [Internet]. 2020 Sept 7 [cited 2025 July 16];4(1). Available from: https:\/\/www.nature.com\/articles\/s41698-020-00132-5.","DOI":"10.1038\/s41698-020-00132-5"},{"issue":"2020","key":"10.1016\/j.ctrv.2025.103039_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/8459303","article-title":"Analysis of molecular pretreated tumor profiles as predictive biomarkers of therapeutic response and survival outcomes after neoadjuvant therapy for rectal cancer in moroccan population","volume":"11","author":"El Otmani","year":"2020","journal-title":"Dis Markers"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103039_b0290","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2019.07.057","article-title":"Mismatch repair system deficiency is associated with response to neoadjuvant chemoradiation in locally advanced rectal cancer","volume":"105","author":"Meillan","year":"2019","journal-title":"Int J Radiation Oncology*Biology*Phys"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103039_b0295","doi-asserted-by":"crossref","first-page":"220","DOI":"10.5152\/tjg.2018.18179","article-title":"Are there predictors that can determine neoadjuvant treatment responses in rectal cancer?","volume":"30","author":"Rak\u0131c\u0131","year":"2019","journal-title":"Turk J Gastroenterol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103039_b0300","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/his.12069","article-title":"Prognostic value of microsatellite instability in sporadic locally advanced rectal cancer following neoadjuvant radiotherapy","volume":"62","author":"Du","year":"2013","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2025.103039_b0305","article-title":"Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy","author":"Charara","year":"2004","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103039_b0310","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.bjc.6604131","article-title":"Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy","volume":"98","author":"Negri","year":"2008","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103039_b0315","article-title":"Prognostic impact of an integrative landscape of clinical, immune, and molecular features in non-metastatic rectal cancer","volume":"7","author":"Iseas","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103039_b0320","first-page":"e109","article-title":"CEA but not MSI is associated with TRG after neoadjuvant chemoradiation in rectal cancer","volume":"64","author":"Qwaider","year":"2021","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ctrv.2025.103039_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.05.528","article-title":"Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","author":"Hofheinz","year":"2025","journal-title":"Annals of Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103039_b0330","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/02841860701802585","article-title":"The \u2018good\u2019, the \u2018bad\u2019, and the \u2018ugly\u2019 rectal cancers","volume":"47","author":"Blomqvist","year":"2008","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103039_b0335","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432034","article-title":"Evolving Standards of Care in the Management of Localized Colorectal Cancer","volume":"44","author":"Weinberg","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103039_b0340","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3390\/cancers12020319","article-title":"Prognostic and predictive molecular biomarkers for colorectal cancer: updates and challenges","volume":"12","author":"Koncina","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2025.103039_b0345","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2023.04.001","article-title":"Increasing FDA-accelerated approval of single-arm trials in oncology (1992 to 2020)","volume":"159","author":"Ribeiro","year":"2023","journal-title":"J Clinical Epidemiol"},{"key":"10.1016\/j.ctrv.2025.103039_b0350","doi-asserted-by":"crossref","unstructured":"Lu F, Wang T, Lu Y, Chen J. Considerations for Single-Arm Trials to Support Accelerated Approval of Oncology Drugs [Internet]. arXiv; 2024 [cited 2025 July 16]. Available from: http:\/\/arxiv.org\/abs\/2405.12437.","DOI":"10.51387\/24-NEJSDS75"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103039_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101209","article-title":"Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit","volume":"8","author":"Mulder","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2025.103039_b0360","unstructured":"Single-arm trials as pivotal evidence for the authorisation of medicines in the EU | European Medicines Agency (EMA) [Internet]. 2023 [cited 2025 July 16]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/single-arm-trials-pivotal-evidence-authorisation-medicines-eu."},{"key":"10.1016\/j.ctrv.2025.103039_b0365","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.suronc.2020.03.009","article-title":"Microsatellite instability and response to neoadjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis","volume":"34","author":"O\u2019Connell","year":"2020","journal-title":"Surgical Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103039_b0370","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Cervantes","year":"2023","journal-title":"Annals of Oncol"},{"key":"10.1016\/j.ctrv.2025.103039_b0375","doi-asserted-by":"crossref","unstructured":"Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, et al. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. 2024 June 1 [cited 2025 July 16]; Available from: https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/2D\/article-e240029.xml.","DOI":"10.6004\/jnccn.2024.0029"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103039_b0380","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.radonc.2015.02.001","article-title":"Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer","volume":"114","author":"Valentini","year":"2015","journal-title":"Radiotherapy and Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103039_b0385","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/annonc\/mdw215","article-title":"PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer","volume":"27","author":"Sclafani","year":"2016","journal-title":"Annals of Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2025.103039_b0390","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clinical Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103039_b0395","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00384-008-0504-2","article-title":"Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group","volume":"23","author":"M\u00fcller","year":"2008","journal-title":"Int J Colorectal Dis"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103039_b0405","first-page":"767","article-title":"Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation","volume":"58","author":"Davis","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103039_b0410","article-title":"In vitro study of radiosensitivity in colorectal cancer cell lines associated with Lynch syndrome","volume":"12","author":"Sun","year":"2024","journal-title":"Front Public Health"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103039_b0415","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/jmg.2006.048660","article-title":"Biallelic mutation of MSH2 in primary human cells is associated with sensitivity to irradiation and altered RAD51 foci kinetics","volume":"44","author":"Barwell","year":"2007","journal-title":"J Med Genet"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103039_b0420","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","article-title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial","volume":"35","author":"Conroy","year":"2024","journal-title":"Annals of Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103039_b0425","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.23.01208","article-title":"Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial","volume":"42","author":"Verheij","year":"2024","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103039_b0430","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","article-title":"Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial","volume":"278","author":"Dijkstra","year":"2023","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103039_b0435","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa2303269","article-title":"Preoperative treatment of locally advanced rectal cancer","volume":"389","author":"Schrag","year":"2023","journal-title":"New England J Medicine"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103039_b0440","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/SLA.0000000000005780","article-title":"Neoadjuvant chemotherapy with CAPOX Versus Chemoradiation for locally advanced rectal cancer with uninvolved Mesorectal Fascia (CONVERT): initial results of a phase III trial","volume":"277","author":"Mei","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2025.103039_b0445","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2025.2026","article-title":"Total neoadjuvant therapy for locally advanced rectal cancer","author":"Audisio","year":"2025","journal-title":"JAMA Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T07:51:22Z","timestamp":1764143482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":88,"alternative-id":["S0305737225001616"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103039","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mismatch repair deficiency\/microsatellite instability (dMMR\/MSI-H) in rectal cancer patients treated with standard neoadjuvant therapy: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103039"}}